Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 +CD25+ regulatory T cells

Nature Medicine

Volumn 11, Issue 11, 2005, Pages 1238-1243

  Zhang, Hua ^a   Chua, Kevin S ^a   Guimond, Martin ^a   Kapoor, Veena ^a   Brown, Margaret V ^b   Fleisher, Thomas A ^b   Long, Lauren M ^a   Bernstein, Donna ^a   Hill, Brenna J ^c   Douek, Daniel C ^c   Berzofsky, Jay A ^a   Carter, Charles S ^b   Read, E J ^b   Helman, Lee J ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; HOMEOSTASIS; HOST; HUMAN; IMMUNE RESPONSE; LYMPHOCYTOPENIA; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SARCOMA;

ADOLESCENT; ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE TRANSFUSION; LYMPHOPENIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; SARCOMA; T-LYMPHOCYTES, REGULATORY;

ANIMALIA;

EID: 30744458573     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1312     Document Type: Article

References (31)

1. Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21 (2001).
2. Brunkow, M.E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68-73 (2001).
3. Shevach, E.M. Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. 18, 423-449 (2000).
4. Sakaguchi, S. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32 (2001).
5. Malek, T.R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167-178 (2002).
6. Bayer, A.L., Yu, A., Adeegbe, D. & Malek, T.R. Essential role for interleukin-2 for CD4(+)CD25(+) Tregulatory cell development during the neonatal period. J. Exp. Med. 201, 769-777 (2005).
7. Furtado, G.C., Curotto de Lafaille, M.A., Kutchukhidze, N. & Lafaille, J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196, 851-857 (2002).
8. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
9. Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268, 1472-1476 (1995).
10. Malek, T.R. & Bayer, A.L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4, 665-674 (2004).
11. Atkins, M.B. Interleukin-2: clinical applications. Semin. Oncol. 29, 12-17 (2002).
12. Murakami, M., Sakamoto, A., Bender, J., Kappler, J. & Marrack, P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA 99, 8832-8837 (2002).
13. Melchionda, F. et al. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8(+) memory cell pool. J. Clin. Invest. 115, 1177-1187 (2005).
14. Baecher-Allan, C., Brown, J.A., Freeman, G.J. & Hafler, D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001).
15. Katlama, C. et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 16, 2027-2034 (2002).
16. Sereti, I. et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J. Clin. Invest. 115, 1839-1847 (2005).
17. Hakim, F.T. et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115, 930-939 (2005).
18. Itoh, M. et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162, 5317-5326 (1999).
19. Hsieh, C.S. et al. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 21, 267-277 (2004).
20. Apostolou, I. & von Boehmer, H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199, 1401-1408 (2004).
21. McHugh, R.S. et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16, 311-323 (2002).
22. Nakamura, K. et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory Tcell activity in both humans and mice. J. Immunol. 172, 834-842 (2004).
23. Fry, T.J. et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 97, 2983-2990 (2001).
24. Khattri, R., Cox, T., Yasayko, S.A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337-342 (2003).
25. Fontenot, J.D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329-341 (2005).
26. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
27. Cozzo, C., Larkin, J., III & Caton, A.J. Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J. Immunol. 171, 5678-5682 (2003).
28. Wang, H.Y. et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
29. Turk, M.J. et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771-782 (2004).
30. Yu, P. et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201, 779-791 (2005).
31. Douek, D.C. et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 355, 1875-1881 (2000).